View ValuationCofinimmo 将来の成長Future 基準チェック /16Cofinimmoの収益は年間0.6%で減少すると予測されていますが、年間利益は年間2.8%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に7% 5.9%なると予測されています。主要情報2.8%収益成長率5.93%EPS成長率Health Care REITs 収益成長0%収益成長率-0.6%将来の株主資本利益率7.02%アナリストカバレッジGood最終更新日15 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Mrics Gielens was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 10Cofinimmo SA(ENXTBR:COFB) dropped from Brussels BEL 20 IndexCofinimmo SA removedお知らせ • Oct 03+ 4 more updatesCofinimmo SA to Report Nine Months, 2026 Results on Oct 23, 2026Cofinimmo SA announced that they will report nine months, 2026 results on Oct 23, 2026お知らせ • May 15Cofinimmo SA announces Annual dividend, payable on May 22, 2025Cofinimmo SA announced Annual dividend of EUR 4.3400 per share payable on May 22, 2025, ex-date on May 20, 2025 and record date on May 21, 2025.Reported Earnings • Oct 27Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €85.3m (down 5.3% from 3Q 2023). Net loss: €274.0k (down 102% from profit in 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 2.6% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance.Reported Earnings • Jul 28Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €87.9m (down 2.5% from 2Q 2023). Net income: €24.6m (up 155% from 2Q 2023). Profit margin: 28% (up from 11% in 2Q 2023). Revenue is expected to decline by 1.6% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 1.9%.お知らせ • Jul 26+ 4 more updatesCofinimmo SA to Report Q3, 2025 Results on Oct 31, 2025Cofinimmo SA announced that they will report Q3, 2025 results Pre-Market on Oct 31, 2025Declared Dividend • May 12Dividend of €4.34 announcedShareholders will receive a dividend of €4.34. Ex-date: 13th May 2024 Payment date: 3rd June 2024 Dividend yield will be 6.5%, which is higher than the industry average of 3.8%.Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: €0.48 (vs €0.53 in 1Q 2023)First quarter 2024 results: EPS: €0.48 (down from €0.53 in 1Q 2023). Revenue: €87.0m (up 2.4% from 1Q 2023). Net income: €17.5m (flat on 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.Reported Earnings • Apr 08Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €389.0m (up 5.8% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 2.9%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 26Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €349.0m (down 5.1% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.Buying Opportunity • Jan 17Now 20% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be €89.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 0.9% per annum. Earnings is also forecast to grow by 48% per annum over the same time period.お知らせ • Oct 28+ 5 more updatesCofinimmo SA to Report First Half, 2024 Results on Jul 26, 2024Cofinimmo SA announced that they will report first half, 2024 results on Jul 26, 2024Reported Earnings • Oct 28Third quarter 2023 earnings released: EPS: €0.34 (vs €4.60 in 3Q 2022)Third quarter 2023 results: EPS: €0.34 (down from €4.60 in 3Q 2022). Revenue: €83.1m (up 5.9% from 3Q 2022). Net income: €11.4m (down 92% from 3Q 2022). Profit margin: 14% (down from 189% in 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.お知らせ • Oct 07Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million.Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,785,805 Price\Range: €60 Transaction Features: Rule 144Aお知らせ • Sep 27An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million.An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million on September 25, 2023.New Risk • Jul 31New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 49% Last year net profit margin: 137% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.5% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (49% net profit margin). Shareholders have been diluted in the past year (5.4% increase in shares outstanding).Reported Earnings • Jul 30Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €85.3m (up 1.2% from 2Q 2022). Net income: €9.64m (down 94% from 2Q 2022). Profit margin: 11% (down from 187% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 30Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €85.3m (up 1.2% from 2Q 2022). Net income: €9.64m (down 94% from 2Q 2022). Profit margin: 11% (down from 187% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.New Risk • Jul 28New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 101% Dividend yield: 8.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.2% operating cash flow to total debt). Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.2% increase in shares outstanding).お知らせ • Jul 14Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home for € 7.35 million.Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home on for €7.35 million July 13, 2023.Cofinimmo SA (ENXTBR:COFB) completed the acquisition of The Park Nursing Home on July 13, 2023.Buying Opportunity • May 15Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be €100, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 1.7% per annum. Earnings is also forecast to grow by 6.6% per annum over the same time period.Upcoming Dividend • May 08Upcoming dividend of €4.34 per share at 7.2% yieldEligible shareholders must have bought the stock before 15 May 2023. Payment date: 17 May 2023. Trailing yield: 7.2%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (6.2%).Buying Opportunity • Apr 25Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €106, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 0.7% per annum. Earnings is forecast to decline by 10% per annum over the same time period.Reported Earnings • Apr 11Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021)Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (up 15% from FY 2021). The current share price is 29% lower than NAV per share. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Buying Opportunity • Mar 24Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.2%. The fair value is estimated to be €98.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 4.4% per annum. Earnings is forecast to decline by 10% per annum over the same time period.Buying Opportunity • Mar 03Now 22% undervaluedOver the last 90 days, the stock is up 1.1%. The fair value is estimated to be €107, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings is forecast to decline by 11% per annum over the same time period.Reported Earnings • Feb 22Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021)Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (flat on FY 2021). The current share price is 27% lower than NAV per share. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Buying Opportunity • Feb 07Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €108, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 5.3% per annum. Earnings is also forecast to grow by 0.09% per annum over the same time period.Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €76.6m (up 6.2% from 3Q 2021). Net income: €148.3m (up 103% from 3Q 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the REITs industry in Europe.Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €79.4m (up 7.6% from 2Q 2021). Net income: €157.6m (up 213% from 2Q 2021). Over the next year, revenue is forecast to decline by 3.0% while the industry in Germany is not expected to grow.お知らせ • Jul 30+ 4 more updatesCofinimmo SA to Report Fiscal Year 2022 Final Results on Apr 07, 2023Cofinimmo SA announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Apr 07, 2023Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Michael Zahn was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • May 09Upcoming dividend of €4.20 per shareEligible shareholders must have bought the stock before 16 May 2022. Payment date: 18 May 2022. Trailing yield: 4.9%. Within top quartile of German dividend payers (4.2%). Higher than average of industry peers (4.4%).Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €79.2m (up 12% from 1Q 2021). Net income: €167.0m (up 271% from 1Q 2021). Over the next year, revenue is forecast to decline by 4.3% while the industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year.Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 10Full year 2021 earnings released: EPS: €8.77 (vs €4.50 in FY 2020)Full year 2021 results: EPS: €8.77 (up from €4.50 in FY 2020). Revenue: €302.0m (up 3.2% from FY 2020). Net income: €260.0m (up 118% from FY 2020). Profit margin: 86% (up from 41% in FY 2020). The increase in margin was primarily driven by lower expenses. Over the next year, revenue is forecast to grow 8.6% while the reits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 4% per year and the company’s share price has also increased by 4% per year.Reported Earnings • Feb 25Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: €8.22 (up from €4.50 in FY 2020). Revenue: €299.6m (up 2.3% from FY 2020). Net income: €260.3m (up 118% from FY 2020). Profit margin: 87% (up from 41% in FY 2020). Revenue missed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 12% while thereits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.お知らせ • Dec 18Cofinimmo SA (ENXTBR:COFB) acquired Hof van Blom from Nijhuis Bouw B.V. for €13 million.Cofinimmo SA (ENXTBR:COFB) acquired Hof van Blom from Nijhuis Bouw B.V. for €13 million on December 16, 2021. Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Hof van Blom from Nijhuis Bouw B.V. on December 16, 2021.Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS €2.44 (vs €1.45 in 3Q 2020)Third quarter 2021 results: Revenue: €72.6m (up 123% from 3Q 2020). Net income: €73.1m (up 87% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Upcoming Dividend • May 10Upcoming dividend of €4.06 per shareEligible shareholders must have bought the stock before 17 May 2021. Payment date: 19 May 2021. Trailing yield: 4.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (3.5%).Reported Earnings • Apr 30First quarter 2021 earnings released: EPS €1.67 (vs €1.64 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €71.0m (down 20% from 1Q 2020). Net income: €45.1m (up 6.9% from 1Q 2020). Profit margin: 64% (up from 48% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Reported Earnings • Apr 12Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €292.7m (up 2.6% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 41% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Reported Earnings • Feb 28Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €259.2m (down 9.2% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 46% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 3.3%. Over the next year, revenue is expected to shrink by 1.1% compared to a 47% growth forecast for the REITs industry in Germany.Is New 90 Day High Low • Feb 11New 90-day high: €130The company is up 1.0% from its price of €129 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €152 per share.Reported Earnings • Jan 17Third quarter 2020 earnings released: EPS €1.45Third quarter 2020 results: Revenue: €32.5m (up 9.0% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 5% per year.Reported Earnings • Nov 21Third quarter 2020 earnings released: EPS €1.45Third quarter 2020 results: Revenue: €32.5m (down 52% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 6% per year.Is New 90 Day High Low • Oct 29New 90-day low: €117The company is down 4.0% from its price of €122 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the REITs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €136 per share.Is New 90 Day High Low • Oct 05New 90-day high: €129The company is up 5.0% from its price of €123 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the REITs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €135 per share.Is New 90 Day High Low • Sep 20New 90-day high: €128The company is up 2.0% from its price of €126 on 22 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €133 per share.業績と収益の成長予測DB:COF - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202838221389N/A312/31/2027369225105N/A712/31/2026356223123N/A23/31/2026383203N/AN/AN/A12/31/2025382213297297N/A9/30/2025390192N/AN/AN/A6/30/2025391134288288N/A3/31/2025392111N/AN/AN/A12/31/202439264279279N/A9/30/2024392-52N/AN/AN/A6/30/2024392-41254255N/A3/31/2024391-55N/AN/AN/A12/31/2023389-55227228N/A9/30/202337949N/AN/AN/A6/30/2023379185223224N/A3/31/2023373333N/AN/AN/A12/31/2022368483209210N/A9/30/2022367565N/AN/AN/A6/30/2022357489205206N/A3/31/2022351382N/AN/AN/A12/31/2021343260199200N/A9/30/2021328189N/AN/AN/A6/30/2021312155185186N/A3/31/2021276122N/AN/AN/A12/31/2020293119178180N/A9/30/2020296170N/AN/AN/A6/30/2020266193166167N/A3/31/2020292222N/AN/AN/A12/31/2019285205N/A169N/A9/30/2019241134N/AN/AN/A6/30/2019270119N/A182N/A3/31/2019259105N/AN/AN/A12/31/2018263146N/A161N/A9/30/2018260186N/AN/AN/A6/30/2018258170N/A140N/A3/31/2018264166N/AN/AN/A12/31/2017263137N/A157N/A9/30/2017267121N/AN/AN/A6/30/2017267128N/A168N/A3/31/2017275134N/AN/AN/A12/31/201625797N/A144N/A9/30/2016253100N/AN/AN/A6/30/201625582N/A148N/A3/31/2016249110N/AN/AN/A12/31/2015255104N/A170N/A9/30/201526076N/AN/AN/A6/30/201526266N/A158N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: COFの予測収益成長率 (年間2.8% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: COFの収益 ( 2.8% ) German市場 ( 17.1% ) よりも低い成長が予測されています。高成長収益: COFの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: COFの収益は今後 3 年間で減少すると予想されています (年間-0.6% )。高い収益成長: COFの収益は今後 3 年間で減少すると予測されています (年間-0.6% )。一株当たり利益成長率予想将来の株主資本利益率将来のROE: COFの 自己資本利益率 は、3年後には低くなると予測されています ( 7 %)。成長企業の発掘7D1Y7D1Y7D1YReal-estate 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 12:16終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cofinimmo SA 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Celine HuynhBarclaysKai KloseBerenbergRobert JonesBNP Paribas17 その他のアナリストを表示
Board Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Mrics Gielens was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 03+ 4 more updatesCofinimmo SA to Report Nine Months, 2026 Results on Oct 23, 2026Cofinimmo SA announced that they will report nine months, 2026 results on Oct 23, 2026
お知らせ • May 15Cofinimmo SA announces Annual dividend, payable on May 22, 2025Cofinimmo SA announced Annual dividend of EUR 4.3400 per share payable on May 22, 2025, ex-date on May 20, 2025 and record date on May 21, 2025.
Reported Earnings • Oct 27Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €85.3m (down 5.3% from 3Q 2023). Net loss: €274.0k (down 102% from profit in 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 2.6% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jul 28Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €87.9m (down 2.5% from 2Q 2023). Net income: €24.6m (up 155% from 2Q 2023). Profit margin: 28% (up from 11% in 2Q 2023). Revenue is expected to decline by 1.6% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 1.9%.
お知らせ • Jul 26+ 4 more updatesCofinimmo SA to Report Q3, 2025 Results on Oct 31, 2025Cofinimmo SA announced that they will report Q3, 2025 results Pre-Market on Oct 31, 2025
Declared Dividend • May 12Dividend of €4.34 announcedShareholders will receive a dividend of €4.34. Ex-date: 13th May 2024 Payment date: 3rd June 2024 Dividend yield will be 6.5%, which is higher than the industry average of 3.8%.
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: €0.48 (vs €0.53 in 1Q 2023)First quarter 2024 results: EPS: €0.48 (down from €0.53 in 1Q 2023). Revenue: €87.0m (up 2.4% from 1Q 2023). Net income: €17.5m (flat on 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
Reported Earnings • Apr 08Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €389.0m (up 5.8% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 2.9%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 26Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €349.0m (down 5.1% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
Buying Opportunity • Jan 17Now 20% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be €89.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 0.9% per annum. Earnings is also forecast to grow by 48% per annum over the same time period.
お知らせ • Oct 28+ 5 more updatesCofinimmo SA to Report First Half, 2024 Results on Jul 26, 2024Cofinimmo SA announced that they will report first half, 2024 results on Jul 26, 2024
Reported Earnings • Oct 28Third quarter 2023 earnings released: EPS: €0.34 (vs €4.60 in 3Q 2022)Third quarter 2023 results: EPS: €0.34 (down from €4.60 in 3Q 2022). Revenue: €83.1m (up 5.9% from 3Q 2022). Net income: €11.4m (down 92% from 3Q 2022). Profit margin: 14% (down from 189% in 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
お知らせ • Oct 07Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million.Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,785,805 Price\Range: €60 Transaction Features: Rule 144A
お知らせ • Sep 27An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million.An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million on September 25, 2023.
New Risk • Jul 31New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 49% Last year net profit margin: 137% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.5% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (49% net profit margin). Shareholders have been diluted in the past year (5.4% increase in shares outstanding).
Reported Earnings • Jul 30Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €85.3m (up 1.2% from 2Q 2022). Net income: €9.64m (down 94% from 2Q 2022). Profit margin: 11% (down from 187% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 30Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €85.3m (up 1.2% from 2Q 2022). Net income: €9.64m (down 94% from 2Q 2022). Profit margin: 11% (down from 187% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
New Risk • Jul 28New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 101% Dividend yield: 8.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.2% operating cash flow to total debt). Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
お知らせ • Jul 14Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home for € 7.35 million.Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home on for €7.35 million July 13, 2023.Cofinimmo SA (ENXTBR:COFB) completed the acquisition of The Park Nursing Home on July 13, 2023.
Buying Opportunity • May 15Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be €100, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 1.7% per annum. Earnings is also forecast to grow by 6.6% per annum over the same time period.
Upcoming Dividend • May 08Upcoming dividend of €4.34 per share at 7.2% yieldEligible shareholders must have bought the stock before 15 May 2023. Payment date: 17 May 2023. Trailing yield: 7.2%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (6.2%).
Buying Opportunity • Apr 25Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €106, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 0.7% per annum. Earnings is forecast to decline by 10% per annum over the same time period.
Reported Earnings • Apr 11Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021)Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (up 15% from FY 2021). The current share price is 29% lower than NAV per share. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Buying Opportunity • Mar 24Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.2%. The fair value is estimated to be €98.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 4.4% per annum. Earnings is forecast to decline by 10% per annum over the same time period.
Buying Opportunity • Mar 03Now 22% undervaluedOver the last 90 days, the stock is up 1.1%. The fair value is estimated to be €107, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings is forecast to decline by 11% per annum over the same time period.
Reported Earnings • Feb 22Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021)Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (flat on FY 2021). The current share price is 27% lower than NAV per share. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Buying Opportunity • Feb 07Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €108, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 5.3% per annum. Earnings is also forecast to grow by 0.09% per annum over the same time period.
Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €76.6m (up 6.2% from 3Q 2021). Net income: €148.3m (up 103% from 3Q 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the REITs industry in Europe.
Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €79.4m (up 7.6% from 2Q 2021). Net income: €157.6m (up 213% from 2Q 2021). Over the next year, revenue is forecast to decline by 3.0% while the industry in Germany is not expected to grow.
お知らせ • Jul 30+ 4 more updatesCofinimmo SA to Report Fiscal Year 2022 Final Results on Apr 07, 2023Cofinimmo SA announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Apr 07, 2023
Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Michael Zahn was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • May 09Upcoming dividend of €4.20 per shareEligible shareholders must have bought the stock before 16 May 2022. Payment date: 18 May 2022. Trailing yield: 4.9%. Within top quartile of German dividend payers (4.2%). Higher than average of industry peers (4.4%).
Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €79.2m (up 12% from 1Q 2021). Net income: €167.0m (up 271% from 1Q 2021). Over the next year, revenue is forecast to decline by 4.3% while the industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year.
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 10Full year 2021 earnings released: EPS: €8.77 (vs €4.50 in FY 2020)Full year 2021 results: EPS: €8.77 (up from €4.50 in FY 2020). Revenue: €302.0m (up 3.2% from FY 2020). Net income: €260.0m (up 118% from FY 2020). Profit margin: 86% (up from 41% in FY 2020). The increase in margin was primarily driven by lower expenses. Over the next year, revenue is forecast to grow 8.6% while the reits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 4% per year and the company’s share price has also increased by 4% per year.
Reported Earnings • Feb 25Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: €8.22 (up from €4.50 in FY 2020). Revenue: €299.6m (up 2.3% from FY 2020). Net income: €260.3m (up 118% from FY 2020). Profit margin: 87% (up from 41% in FY 2020). Revenue missed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 12% while thereits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.
お知らせ • Dec 18Cofinimmo SA (ENXTBR:COFB) acquired Hof van Blom from Nijhuis Bouw B.V. for €13 million.Cofinimmo SA (ENXTBR:COFB) acquired Hof van Blom from Nijhuis Bouw B.V. for €13 million on December 16, 2021. Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Hof van Blom from Nijhuis Bouw B.V. on December 16, 2021.
Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS €2.44 (vs €1.45 in 3Q 2020)Third quarter 2021 results: Revenue: €72.6m (up 123% from 3Q 2020). Net income: €73.1m (up 87% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Upcoming Dividend • May 10Upcoming dividend of €4.06 per shareEligible shareholders must have bought the stock before 17 May 2021. Payment date: 19 May 2021. Trailing yield: 4.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (3.5%).
Reported Earnings • Apr 30First quarter 2021 earnings released: EPS €1.67 (vs €1.64 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €71.0m (down 20% from 1Q 2020). Net income: €45.1m (up 6.9% from 1Q 2020). Profit margin: 64% (up from 48% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 12Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €292.7m (up 2.6% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 41% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 28Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €259.2m (down 9.2% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 46% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 3.3%. Over the next year, revenue is expected to shrink by 1.1% compared to a 47% growth forecast for the REITs industry in Germany.
Is New 90 Day High Low • Feb 11New 90-day high: €130The company is up 1.0% from its price of €129 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €152 per share.
Reported Earnings • Jan 17Third quarter 2020 earnings released: EPS €1.45Third quarter 2020 results: Revenue: €32.5m (up 9.0% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 5% per year.
Reported Earnings • Nov 21Third quarter 2020 earnings released: EPS €1.45Third quarter 2020 results: Revenue: €32.5m (down 52% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 6% per year.
Is New 90 Day High Low • Oct 29New 90-day low: €117The company is down 4.0% from its price of €122 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the REITs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €136 per share.
Is New 90 Day High Low • Oct 05New 90-day high: €129The company is up 5.0% from its price of €123 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the REITs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €135 per share.
Is New 90 Day High Low • Sep 20New 90-day high: €128The company is up 2.0% from its price of €126 on 22 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €133 per share.